Working… Menu

Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00855179
Recruitment Status : Completed
First Posted : March 4, 2009
Last Update Posted : May 16, 2014
Information provided by:
Boehringer Ingelheim

Brief Summary:
To assess the efficacy and tolerability of Antistax film coated tablets in patients with chronic venous insufficiency (CVI, CEAP Classification: Clinical class 3 and 4a).

Condition or disease Intervention/treatment Phase
Venous Insufficiency Drug: Red vine leaf extract (AS 195) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 720 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency
Study Start Date : March 2009
Actual Primary Completion Date : November 2009

Arm Intervention/treatment
Active Comparator: Antistax film-coated tablets 360 mg
Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
Drug: Red vine leaf extract (AS 195)
Antistax film-coated tablet 360 mg

Placebo Comparator: Placebo
Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
Drug: Placebo
Placebo tablets identical to those containing Anstistax 360 mg

Primary Outcome Measures :
  1. Change from baseline in limb volume determination at day 84 (water displacement method) [ Time Frame: 84 days ]

Secondary Outcome Measures :
  1. Change from baseline in limb volume determination at day 21 and 42 (water displacement method) [ Time Frame: 21 and 42 days ]
  2. Change from baseline in the subjective symptoms of CVI (tired, heavy legs, sensation of tension in the legs) pain in the legs) measured by Visual Analogue Scales at day 21,42 and 84 [ Time Frame: 21, 42 and 84 days ]
  3. Incidence of adverse events [ Time Frame: 84 days ]
  4. Global assessment of efficacy by the patient at day 84 [ Time Frame: 84 days ]
  5. Change from baseline in the calf circumference at day 21, 42 and 84 [ Time Frame: 21, 42 and 84 days ]
  6. Global assessment of efficacy by the investigator at day 84 [ Time Frame: 84 days ]
  7. Time to improvement in symptoms [ Time Frame: 84 days ]
  8. Vital signs (pulse rate, blood pressure) [ Time Frame: 84 days ]
  9. Number of patients with abnormal Serum Laboratory Parameters [ Time Frame: 84 days ]
  10. Global assessment of tolerability by the patient at day 84 [ Time Frame: 84 days ]
  11. Global assessment of tolerability by the investigator at day 84 [ Time Frame: 84 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or Female
  2. 18 years of age or older
  3. CVI, Clinical Class 3 and Class 4a according to the CEAP classification
  4. Presence of stable edema determined by a pretibial pit after 30 seconds pressure with the thumb documented by a photo
  5. Stable and reproducible status of swelling documented by difference of less than 150g between screening and baseline as determined by water displacement method
  6. Presence of moderate to severe varicoses (dilated, tortuous veins in the subcutaneous tissue with a diameter of more than 3mm
  7. Intensity of leg pain at least 5 cm on the Visual Analogue Scale at baseline and presence of hyperpigmentation or eczema and presence of moderate to severe edema
  8. Willing and able to give written informed consent prior to participation in the trial
  9. Patients expected to be compliant (compliance with run-in medication greater than 80% as checked by drug count)

Exclusion Criteria:

  1. Decompensated cardiac insufficiency according to the New York Heart Association (NYHA) classification III and IV for cardiac patients
  2. Edema not due to venous disease of the legs(e.g. latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
  3. Severe skin changes, e.g. lipodermatosclerosis
  4. Current florid venous ulcer
  5. Peripheral arterial disease (ankle/arm pressure index less than 0.9)
  6. Untreated or insufficiently controlled hypertension
  7. Current acute phlebitis of thrombosis with the last 3 months. Post-thrombotic syndrome, who do not currently receive an anticoagulation treatment can be included in the trial
  8. Renal insufficiency
  9. Liver disease; hepatic insufficiency
  10. Hyper- or hypocalcemia
  11. Malignancies
  12. Anamnestic indications of diabetic microangiopathy or polyneuropathy
  13. Drug and/or alcohol abuse
  14. Severe climacteric complaints; changes in or initiation of post-menopausal hormone replacement therapy within the last 3 months
  15. Immobility
  16. Avalvulia
  17. Klippel-Trénaunay-Weber-Syndrome
  18. State after pulmonary embolism
  19. Recognized hypersensitivity to the trial drug ingredients
  20. Clinical indication for a specific phlebologic treatment, e.g. compression treatment phlebectomy, etc

Previous Treatments:

  1. Compression therapy and/or wearing of support stockings less than 2 weeks prior to the visit at baseline
  2. Venous surgery or sclerotherapy with the last 3 months at the leg used for volumetry
  3. Treatment with drugs affecting the veins less than 4 weeks prior to visit 1
  4. Changes in or unstable response to treatment with theophylline, cardiac glycosides, ACE-inhibitors, calcium antagonists, or laxatives with the last 2 weeks prior to visit 1

Concomitant Treatment:

  1. Compression therapy
  2. Diuretics
  3. Nitrates
  4. Ergot alkaloids
  5. All preparations which are used as compounds for venous therapy in CVI (e.g. vasoprotectives for antivaricose therapy, preparations with heparin, sclerosing agents, flavonoid-containing preparations, other phytopharmaceuticals
  6. Other drugs active on blood vessels and circulation
  7. Extensive use of laxatives
  8. Anticipated changes in the intake of hormones, ie contraceptives
  9. Scheduled major surgery requiring full anesthesia

Other exclusion Criteria:

  1. Previously studied under the present protocol
  2. Participation in another clinical trial within less than 90 days prior to Visit 1
  3. Participation in another clinical trial during the present trial
  4. Patient is investigator, co-investigator, trial nurse in this trial or is a relative of the investigator, co-investigator or trial nurse in this trial
  5. Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only; reliable contraceptive methods are hormonal contraceptives, intrauterine devices, sexual abstinence of sterilization)
  6. Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  7. Patients in bad general health state according to the investigator's judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00855179

Layout table for location information
1138.11.49004 Boehringer Ingelheim Investigational Site
Berlin, Germany
1138.11.49016 Boehringer Ingelheim Investigational Site
Berlin, Germany
1138.11.49019 Boehringer Ingelheim Investigational Site
Bochum, Germany
1138.11.49014 Boehringer Ingelheim Investigational Site
Bonn, Germany
1138.11.49023 Boehringer Ingelheim Investigational Site
Breisach, Germany
1138.11.49003 Boehringer Ingelheim Investigational Site
Coburg, Germany
1138.11.49024 Boehringer Ingelheim Investigational Site
Dülmen, Germany
1138.11.49007 Boehringer Ingelheim Investigational Site
Freiburg, Germany
1138.11.49020 Boehringer Ingelheim Investigational Site
Freiburg, Germany
1138.11.49009 Boehringer Ingelheim Investigational Site
Greifswald, Germany
1138.11.49013 Boehringer Ingelheim Investigational Site
Köln, Germany
1138.11.49010 Boehringer Ingelheim Investigational Site
Lübeck, Germany
1138.11.49011 Boehringer Ingelheim Investigational Site
Mainz, Germany
1138.11.49012 Boehringer Ingelheim Investigational Site
Minden, Germany
1138.11.49005 Boehringer Ingelheim Investigational Site
München, Germany
1138.11.49022 Boehringer Ingelheim Investigational Site
Oberhausen, Germany
1138.11.49002 Boehringer Ingelheim Investigational Site
Oberkirch, Germany
1138.11.49001 Boehringer Ingelheim Investigational Site
Rottach-Egern, Germany
1138.11.49006 Boehringer Ingelheim Investigational Site
Rottweil, Germany
1138.11.49018 Boehringer Ingelheim Investigational Site
Tübingen, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00855179     History of Changes
Other Study ID Numbers: 1138.11
First Posted: March 4, 2009    Key Record Dates
Last Update Posted: May 16, 2014
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Insufficiency
Vascular Diseases
Cardiovascular Diseases